A new study presented at the ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago reveals that long-term intake of denosumab in postmenopausal women suffering from osteoporosis was linked with increased bone density, low rate of fractures and a favorable benefit/risk profile. "This study provides reassurance to physicians and their patients that long-term treatment with denosumab for at least 8 years ...
Read More
You have just read an article categorized health
titled Postmenopausal Women Taking Denosumab Have Low Risk of Fracture.
Written by:
editor -
Thursday, June 26, 2014
There are currently no comments for "Postmenopausal Women Taking Denosumab Have Low Risk of Fracture"
Post a Comment